reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PSTG PURE STORAGE INC. CLASS A
MDWD MEDIWOUND
LE LANDS' END INC.
HUBS HUBSPOT INC.
ARN ARNOLD GEORG AG
ANAB ANAPTYSBIO INC.
LILA LIBERTY LATIN AMERICA A
CRNX CRINETICS PHARMACEUTICALS
IIIV I3 VERTICALS
EVER EVERQUOTE
BDCO BLUE DOLPHIN ENERGY CO.
ABEO ABEO SA
LYFT LYFT
AEYE AUDIOEYE INC
CRMD CORMEDIX INC.
BDTX BLACK DIAMOND THERAPEUTICS
NRIX NURIX THERAPEUTICS
VITL VITAL FARMS
ALXO ALX ONCOLOGY HOLDINGS
TCRX TSCAN THERAPEUTICS INC
VERA VERA THERAPEUTICS INC
RXST RXSIGHT INC
MAX MEDIAALPHA INC
KRT KARAT PACKAGING INC
SERA SERA PROGNOSTICS INC
ELVN ONTO INNOVATION INC.
IZM IMARA INC
AVGD ICZOOM GROUP INC
ANG AV-GAD HLDGS LTD
EGIO ANGLOGOLD ASHANTI LIMITED
QTTB EDGIO INC.
PROP Q32 BIO INC
AKA PRAIRIE OPERATING CO.
IDR AKA BRANDS HOLDING CORP
1225 IDAHO STRATEGIC RESOURCES INC
AFRISTRAT INV HLDGS LTD
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under...
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its common stock to ten new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employee...
Molecular Templates Presents Interim Data from MT-6402 Phase I Study i...
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Result...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023. Company Highlights Durable si...
Molecular Templates Announces $9.5 Million Private Placement Offering ...
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced today it has entered into a definitive amended and restated secu...
Crinetics Announces Positive Topline Results from Phase 2 Trial of Pal...
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements Paltusotine was Generally Well-Tolerated and Showed an Overall PK Profile Consistent with Prior Studies Results Confirm Initial Positive Data Previously Reported Management to Host a Conference Call Today at 4:30 p.m. Eastern Time SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) a clinical stage pharmaceutical compa...
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under...
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its common stock to five new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees...
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. Provides Interim Update Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, toda...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Fi...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024 Phase 2 Study of Paltusotine in Carcinoid Syndrome Full Topline Results Expected 1H 2024 Announced a $350 Million Private Placement Equity Financing Management Hosting Conference Call and Webcast at 4:30 p.m. ET Today SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today reported financial results for the fourth quarter and full ...
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Privat...
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics” or the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist investors in an oversubscr...
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 ...
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Wednesday, February 28th @ 4:30 PM ET Domestic:1-888-886 -7786International:1-416-764-8658 P...
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Un...
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on February 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 73,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the empl...
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare L...
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference. Oppenheimer 34rd Annual Healthcare Conference, February 13 – 14 Format: Virtual PresentationDate: Wednesday, February 14, 2024Time: ...
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Und...
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on January 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 112,500 shares of its common stock to eight new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the empl...
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morga...
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that , founder and chief executive officer of Crinetics, will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 8-11, 2024. Details of the corporate presentation are as follows: Date:Tuesday, January 9, 2024Time:3:45 p.m. Pacific TimeRoom:Borgia Room The live and archived webcast will be accessible on the page in the Investors section on the Crin...
Crinetics Announces Positive Initial Findings from Ongoing Open-Label ...
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was Consistent with Prior Studies Phase 2 Study Enrollment is Complete (N=36), and Topline Results Expected in 1H 2024 Management to Host a Conference Call Today at 5:00 p.m. Eastern Time SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX)...
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Un...
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on December 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 94,000 shares of its common stock to six new non-executive employees under ...
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferen...
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida and the Piper Sandler 35th Annual Healthcare Conference in New York City. Details of the fireside chats are as follows: 6th Annual Evercore ISI HealthCONx Conference:Date: Tuesday, November 28, 2023Time: 3:50 p.m. Eastern Time Piper Sandler 35th Annual Healthcare Conference:Date: Thursday, November 30, 2...
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results...
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the third quarter of 2023. Eric Poma, PhD., Chief Executive and Chief...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.